MBOT - Microbot Medical Inc Stock Price, Fair Value and News

0.95USD-0.02 (-2.06%)Delayed

Market Summary

USD0.95-0.02

Delayed

-2.06%

MBOT Stock Price

View Fullscreen

MBOT RSI Chart

MBOT Valuation

Market Cap

13.7M

Price/Earnings (Trailing)

-1.33

Price/Sales (Trailing)

117.22

Price/Free Cashflow

-1.75

MBOT Price/Sales (Trailing)

MBOT Profitability

Return on Equity

-166.34%

Return on Assets

-139.24%

Free Cashflow Yield

-57%

MBOT Fundamentals

MBOT Revenue

Revenue (TTM)

114.2K

MBOT Earnings

Earnings (TTM)

-10.3M

Earnings Growth (Yr)

16.89%

Earnings Growth (Qtr)

24.83%

Breaking Down MBOT Revenue

Last 7 days

3.3%

Last 30 days

5.6%

Last 90 days

-26.4%

Trailing 12 Months

-16.4%

How does MBOT drawdown profile look like?

MBOT Financial Health

Current Ratio

5.92

Debt/Equity

0.04

Debt/Cashflow

-31.63

MBOT Investor Care

Shares Dilution (1Y)

77.10%

Diluted EPS (TTM)

-0.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2016	119.3K	118.5K	114.2K	0
2015	1.4M	994.0K	555.5K	116.9K
2014	943.5K	684.8K	442.0K	1.0M
2013	1.0M	1.0M	1.1M	1.2M
2012	1.6M	1.7M	1.7M	1.4M
2011	1.4M	1.4M	1.4M	1.2M
2010	0	1.1M	1.3M	1.4M
2009	0	0	0	992.9K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Microbot Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 19, 2020	bornstein yoseph	sold	-38,734	7.9358	-4,881	-
Oct 12, 2020	bornstein yoseph	sold	-156,898	7.8449	-20,000	-
Oct 05, 2020	bornstein yoseph	sold	-156,898	7.8449	-20,000	-
Oct 05, 2020	bornstein yoseph	sold	-154,850	7.7425	-20,000	-
Aug 17, 2020	bornstein yoseph	sold	-154,093	10.192	-15,119	-
Dec 23, 2019	gadot harel	sold	-400,000	10.00	-40,000	chairman, president and ceo
Jan 16, 2019	alliance investment management ltd	bought	15,432	10.9916	1,404	-
Jan 16, 2019	alliance investment management ltd	sold	-76,288	10.3093	-7,400	-
Jan 15, 2019	alliance investment management ltd	bought	184,139	9.3982	19,593	-
Jan 15, 2019	alliance investment management ltd	sold	-1,220,170	11.778	-103,597	-

Which funds bought or sold MBOT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Beacon Capital Management, LLC	unchanged	-	-960	7,380	-%
May 15, 2024	Hilltop Holdings Inc.	added	28.76	-1,144	32,212	-%
May 15, 2024	Royal Bank of Canada	added	3,277	2,000	2,000	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	new	-	1.00	1.00	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-18,929	-	-%
May 15, 2024	Hudson Bay Capital Management LP	new	-	482,863	482,863	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	reduced	-26.04	-14,796	18,429	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	sold off	-100	-492,000	-	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	unchanged	-	-943	2,829	-%
May 15, 2024	BARCLAYS PLC	unchanged	-	-	-	-%

Are Funds Buying or Selling MBOT?

Are funds buying MBOT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MBOT

No. of Funds

Unveiling Microbot Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	687,654	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	799,180	SC 13G
Jan 20, 2021	chasing value asset management inc.	8.6%	610,657	SC 13G
Jan 02, 2020	gadot harel	4.04%	296,463	SC 13D/A
Oct 21, 2019	mona joseph	5.69%	2,395,495	SC 13G

Recent SEC filings of Microbot Medical Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	424B3	Prospectus Filed
May 15, 2024	10-Q	Quarterly Report
Apr 29, 2024	8-K	Current Report
Apr 25, 2024	424B3	Prospectus Filed
Apr 24, 2024	8-K	Current Report
Apr 16, 2024	424B3	Prospectus Filed
Apr 15, 2024	8-K	Current Report
Apr 04, 2024	424B3	Prospectus Filed
Apr 03, 2024	EFFECT	EFFECT
Apr 01, 2024	S-1/A	Initial Public Offering

Peers (Alternatives to Microbot Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Microbot Medical Inc News

Latest updates

Microbot Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2012Q3	2012Q2	2012Q1	2011Q4
Revenue	11.8%	32,762	29,311	23,164	29,000	37,030	30,131	456,566	883,000	883,157	82,000	23,000	24,000	313,000	324,792	281,697	284,200	211,000	264,000	249,000	644,000	541,520
Gross Profit	-	-	-	-	-	-	-	-	-	-	211,501	164,107	252,204	226,110	239,049	204,124	217,359	156,029	192,104	184,557	572,077	494,099
Operating Expenses	-78.5%	1,912,631	8,913,264	9,837,039	8,528,000	10,024,961	9,302,714	8,981,387	10,612,000	10,611,875	6,462,000	7,983,000	6,866,000	9,341,000	6,628,000	6,131,000	6,165,000	6,949,000	5,269,000	5,534,000	5,898,000	7,807,408
Interest Expenses	21090.6%	27,124	128	27,901	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-11.5%	7.00	8.00	9.00	11.00	6.00	10.00	7.00	11.00	14.00	17.00	20.00	22.00	24.00	26.00	28.00	30.00	31.00	37.00	11.00	13.00	14.00
Current Assets	-11.6%	7.00	8.00	8.00	10.00	6.00	9.00	7.00	10.00	13.00	16.00	19.00	21.00	23.00	25.00	27.00	29.00	30.00	36.00	10.00	12.00	13.00
Cash Equivalents	-52.9%	1.00	2.00	1.00	6.00	2.00	2.00	4.00	7.00	10.00	13.00	13.00	16.00	18.00	20.00	27.00	28.00	30.00	29.00	4.00	5.00	5.00
Net PPE	-9.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-68.6%	1.00	4.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	6.00	5.00	5.00	5.00
Current Liabilities	-68.8%	1.00	4.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	5.00	5.00	4.00	4.00
Shareholder's Equity	37.0%	6.00	5.00	7.00	9.00	5.00	7.00	6.00	9.00	12.00	14.00	18.00	20.00	22.00	24.00	26.00	28.00	30.00	32.00	6.00	8.00	9.00
Retained Earnings	-3.0%	-81.87	-79.50	-76.35	-73.90	-71.61	-68.76	-65.76	-62.29	-58.78	-55.59	-51.73	-49.18	-46.67	-44.28	-41.64	-39.17	-37.32	-35.11	-33.24	-31.37	-29.82
Additional Paid-In Capital	4.8%	88.00	84.00	84.00	83.00	76.00	76.00	71.00	71.00	70.00	70.00	70.00	69.00	69.00	69.00	68.00	67.00	67.00	70.00	43.00	43.00	42.00
Shares Outstanding	23.0%	14.00	12.00	12.00	12.00	8.00	8.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	-	-	-	-	-	-	-
Float	-	-	-	-	38.00	-	-	-	35.00	-	-	-	56.00	-	-	-	46.00	-	-	-	20.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-32.9%	-2,420	-1,821	-1,655	-1,854	-3,203	-2,463	-2,955	-3,124	-3,007	-2,887	-2,176	-2,297	-1,994	-1,870	-1,694	-1,342	-2,346	-1,920	-1,331	-477	-2,723
Share Based Compensation	52.5%	453	297	336	349	412	430	461	432	429	370	307	299	410	469	559	566	343	193	296	295	315
Cashflow From Investing	-143.4%	-1,284	2,957	-2,572	-1,295	2,883	-3,753	-5.00	-62.00	-16.00	2,955	-14.00	-6.00	265	-5,006	-7.00	-8.00	2,253	43.00	-	-	-2,496
Cashflow From Financing	-	2,397	-	-161	6,719	-	-	-	-	-	-	-	-	-	-	-	-	-3,375	27,208	-	-	9,562

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MBOT Income Statement

2024-03-31

Interim Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Research and development, net	$ (1,169)	$ (1,617)
General and administrative	(1,215)	(1,302)
Operating loss	(2,384)	(2,919)
Financing income, net	13	66
Net loss	$ (2,371)	$ (2,853)
Basic net loss per share	$ (0.17)	$ (0.36)
Diluted net loss per share	$ (0.17)	$ (0.36)
Basic weighted average common shares outstanding	14,055,973	8,013,295
Diluted weighted average common shares outstanding	14,055,973	8,013,295

MBOT Balance Sheet

2024-03-31

Interim Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,162	$ 2,468
Marketable securities	5,187	3,917
Restricted cash	48	49
Insurance recovery receivable related to legal settlement and legal expenses		1,335
Prepaid expenses and other current assets	603	152
Total current assets	7,000	7,921
Property and equipment, net	132	146
Operating right-of-use assets	235	260
Total assets	7,367	8,327
Current liabilities:
Accounts payable	96	357
Lease liabilities	191	191
Legal settlement accrual		2,211
Accrued liabilities	896	1,027
Total current liabilities	1,183	3,786
Non-current liabilities:
Long-term lease liabilities	17	40
Total liabilities	1,200	3,826
Shareholders’ equity:
Common stock; $0.01 par value; 60,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 14,398,964 and 11,707,317 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively.	145	118
Additional paid-in capital	87,894	83,884
Accumulated deficit	(81,872)	(79,501)
Total shareholders’ equity	6,167	4,501
Total liabilities and shareholders’ equity	$ 7,367	$ 8,327

About Microbot Medical Inc

Microbot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, a robotic system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination. In addition, it provides One & Done Technology, an endovascular robotic system for a range of applications in cardiovascular, peripheral vascular, and neurovascular spaces; and NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. Further, the company offers ViRob, an autonomous crawling micro-robot which can be controlled remotely to navigate and crawl in different natural spaces within the human body, including blood vessels, digestive tract, and respiratory system, as well as artificial spaces, such as shunts, catheters, ports, etc. Additionally, it provides ipCAT, a disposable self-propelled locomotive device that is designed to advance in tubular anatomies. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is headquartered in Hingham, Massachusetts.

CEO	Mr. Harel Gadot
WEBSITE	https://microbotmedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	18

Microbot Medical Inc Frequently Asked Questions

What is the ticker symbol for Microbot Medical Inc? What does MBOT stand for in stocks?

MBOT is the stock ticker symbol of Microbot Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Microbot Medical Inc (MBOT)?

As of Fri May 17 2024, market cap of Microbot Medical Inc is 13.68 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MBOT stock?

You can check MBOT's fair value in chart for subscribers.

What is the fair value of MBOT stock?

You can check MBOT's fair value in chart for subscribers. The fair value of Microbot Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Microbot Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MBOT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Microbot Medical Inc a good stock to buy?

The fair value guage provides a quick view whether MBOT is over valued or under valued. Whether Microbot Medical Inc is cheap or expensive depends on the assumptions which impact Microbot Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MBOT.

What is Microbot Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MBOT's PE ratio (Price to Earnings) is -1.33 and Price to Sales (PS) ratio is 117.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MBOT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Microbot Medical Inc's stock?

In the past 10 years, Microbot Medical Inc has provided -0.54 (multiply by 100 for percentage) rate of return.